Hosted on MSN2d
NanoKnife gains FDA clearance for prostate tissue ablation
AngioDynamics has won US Food and Drug Administration (FDA) clearance for its NanoKnife system to be used in prostate cancer ...
FierceBiotech1d
FDA clears AngioDynamics’ NanoKnife pulsed field ablation system for prostate cancer
AngioDynamics has obtained an FDA green light for its NanoKnife prostate cancer ablation system, designed to precisely target ...
MassDevice2d
AngioDynamics wins FDA clearance for NanoKnife system in prostate tissue ablation
AngioDynamics received FDA 510(k) clearance for its NanoKnife system for prostate tissue ablation in intermediate-risk ...
Zacks.com on MSN1d
ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife
AngioDynamics, Inc. ANGO, yesterday, announced the receipt of the FDA’s 510(k) clearance for the NanoKnife System for ...
AngioDynamics Shares at 52-Week High After FDA Clears NanoKnife
Shares of AngioDynamics hit a 52-week high after the company's NanoKnife System for prostate tissue ablation received regulatory clearance. The stock jumped almost 35% to a high of $9.42 in early ...
Yahoo Finance1mon
AngioDynamics launches long-term study of NanoKnife for prostate cancer
UCLH was the first facility in the UK’s National Health Service (NHS) to use NanoKnife to treat prostate cancer and provide standardised patient selection, treatment, and long-term follow-up.
AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options ...